Voyager Therapeutics (FRA:VT6) Marketable Securities: €84.91 Mil (As of Mar. 2026)


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
52 GF Score
Price €3.06
GF Value €1.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Marketable Securities?

Voyager Therapeutics FRA:VT6 -2.05% 52 Marketable Securities is €84.91 Mil as of Mar. 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 52/100 and a GF Value™ of €1.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Voyager Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was €84.91 Mil.

Voyager Therapeutics's annual Marketable Securities increased from Dec. 2023 (€148.62 Mil) to Dec. 2024 (€186.53 Mil) but then declined from Dec. 2024 (€186.53 Mil) to Dec. 2025 (€112.00 Mil).

Voyager Therapeutics  (FRA:VT6) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Voyager Therapeutics Marketable Securities Related Terms

Voyager Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Marketable Securities Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.37 18.78 148.62 186.53 112.00

Voyager Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 149.17 0.00 0.00 112.00 84.91
FRA:VT6
52GF Score
Voyager Therapeutics Inc FRA:VT6
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €84.91 Mil mean?
Voyager Therapeutics (FRA:VT6) has a Marketable Securities of €84.91 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Marketable Securities too high?
Voyager Therapeutics' current Marketable Securities is €84.91 Mil. Overall, Voyager Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Marketable Securities compare to KROS and CDXS?
Voyager Therapeutics' Marketable Securities of €84.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Marketable Securities is €84.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.41, compared to a current price of €3.06 — trading 116.7% above its estimated fair value. The current Marketable Securities is €84.91 Mil. Voyager Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Marketable Securities is €84.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.06 is trading 116.7% above its estimated GF Value™ of €1.41. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Marketable Securities: €84.91 Mil
  • GF Value™: €1.41 vs. price of €3.06 (116.7% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for FRA:VT6

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€1.41
GF Value